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abstract
PURPOSE Previous studies of hypofractionated adjuvant whole-breast radiotherapy for early breast cancer
established a 15- or 16-fraction (fr) regimen as standard. The FAST Trial (CRUKE/04/015) evaluated normal
tissue effects (NTE) and disease outcomes after 5-fr regimens. Ten-year results are presented.
METHODS Women $ 50 years of age with low-risk invasive breast carcinoma (pT1-2 pN0) were randomly
assigned to 50 Gy/25 fr (5 weeks) or 30 or 28.5 Gy in 5 once-weekly fr of 6.0 or 5.7 Gy. The primary end point
was change in photographic breast appearance at 2 and 5 years; secondary end points were physician as-
sessments of NTE and local tumor control. Odds ratios (ORs) from longitudinal analyses compared regimens.
RESULTS A total of 915 women were recruited from 18 UK centers (2004-2007). Five-year photographs were
available for 615/862 (71%) eligible patients. ORs for change in photographic breast appearance were 1.64
(95%CI, 1.08 to 2.49;P5 .019) for 30Gy and 1.10 (95%CI, 0.70 to 1.71;P5 .686) for 28.5 Gy versus 50Gy.a/b
estimate for photographic end point was 2.7 Gy (95%CI, 1.5 to 3.9 Gy), giving a 5-fr schedule of 28 Gy (95%CI, 26
to 30 Gy) estimated to be isoeffective with 50 Gy/25 fr. ORs for any moderate/marked physician-assessed breast
NTE (shrinkage, induration, telangiectasia, edema) were 2.12 (95%CI, 1.55 to 2.89; P, .001) for 30 Gy and 1.22
(95% CI, 0.87 to 1.72; P5 .248) for 28.5 Gy versus 50 Gy. With 9.9 years median follow-up, 11 ipsilateral breast
cancer events (50 Gy: 3; 30 Gy: 4; 28.5 Gy: 4) and 96 deaths (50 Gy: 30; 30 Gy: 33; 28.5 Gy: 33) have occurred.
CONCLUSION At 10 years, there was no significant difference in NTE rates after 28.5 Gy/5 fr compared with
50 Gy/25 fr, but NTE were higher after 30 Gy/5 fr. Results confirm the published 3-year findings that a once-
weekly 5-fr schedule of whole-breast radiotherapy can be identified that appears to be radiobiologically
comparable for NTE to a conventionally fractionated regimen.
J Clin Oncol 38. © 2020 by American Society of Clinical Oncology
Licensed under the Creative Commons Attribution 4.0 License
INTRODUCTION
Ten-year results of 4 randomized trials totaling
. 7,000 patients confirm the safety and efficacy of
hypofractionated radiotherapy after primary surgery for
early breast cancer.1-4 The UK START-B and Ontario
trials established 15- and 16-fraction schedules as
new standards of care delivered over 21-22 days.5-7
Sensitivity to fraction size was tested in the START pilot
and START-A trials by controlling for treatment time,
generating an a/b estimate of 3.5 Gy (95% CI, 1.2 to
5.7) for tumor control, comparable to that for late
adverse effects.2,4,8 Fifteen- or 16-fraction regimens
are unlikely to represent the clinical limits of hypo-
fractionation, and 3-year adverse effects of 5-fraction
schedules in the UK FAST trial were reported in 2011.9
In FAST, 5.7 or 6.0 Gy once weekly were tested against
50 Gy in 25 fractions, the standard of care at the time.
The explanatory trial design allowed interpolation be-
tween 2 5-fraction schedules that suggested a schedule
equivalent to 50 Gy in 25 fractions in terms of late
adverse effects. Five fractions of 5.7 and 6.0 Gy were
predicted to be radiobiologically equivalent to 25
fractions of 2.0 Gy, assuming a/b values of 3.0 and
4.0 Gy for late normal tissue responses and tumor
control, respectively.10 At a median follow-up of 3 years,
28.5 Gy in 5 fractions was comparable to 50 Gy in 25
fractions andmilder than 30 Gy in 5 fractions in terms of
adverse effects in the breast.9 This manuscript presents
the 5-year results for change in photographic breast
appearance and physician assessments of breast
normal tissue effects (NTE) up to 10 years after ra-
diotherapy, as well as breast cancer disease events.
METHODS
Patients
FAST is a multicenter, phase III randomized controlled
trial. Full details of trial design, eligibility criteria, radio-
therapy planning and delivery, and study procedures
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have been presented previously (Protocol, online only).9 Eli-
gible patients were women having invasive early breast cancer
age $ 50 years, pathologic tumor size , 3 cm, axillary node
negative, breast-conserving surgery with complete micro-
scopic resection, and whole-breast radiotherapy. Patients
requiring mastectomy, lymphatic radiotherapy, tumor bed
boost, or cytotoxic therapy were ineligible.
Patients were randomly assigned (1:1:1) to receive 50 Gy in
25 fractions of 2.0 Gy, 30 Gy in 5 once-weekly fractions of
6.0 Gy, or 28.5 Gy in 5 once-weekly fractions of 5.7 Gy.
Random assignment was performed by telephone or fax
from the recruiting center to the Clinical Trials and Statistics
Unit, Institute of Cancer Research, London. Computer-
generated random permuted blocks stratified by partici-
pating center were used. Treatment allocation was not
blinded because of the nature of the intervention.
All patients provided written informed consent. FAST
(CRUKE/04/015) was approved by the national South-West
Multicentre Research Ethics Committee (04/MRE06/17)
and the local ethics committees of participating centers.
FAST was sponsored by The Institute of Cancer Research
and is registered as an International Standard Randomized
Controlled Trial (ISRCTN62488883).
Radiotherapy
Patients lay supine on an inclined plane in a position that
remained unchanged during imaging/simulation and treat-
ment, verified by orthogonal laser beams. Clinical target
volume included soft tissues of the whole breast down to deep
fascia but not including underlying muscle, ribcage, overlying
skin, or excision scar. Planning target volume included the
entire breast with 1-cm margins to palpable breast tissue.
Medial and lateral borders did not normally extend beyond the
anterior midline or the midaxilla. Margins were reduced in
selected patients if the tumor bed did not encroach, to exclude
or reduce the volume of heart and/or lungwithin the high-dose
volume. The deep margin extended down to the deep fascia.
Transverse cross-sections of the patient were taken through
the center of the planning target volume; a minimum of 5
slices was recommended, spaced appropriately. Sixteen
out of 18 centers used full-dose compensation with com-
puterized tomography; others used optical outlining de-
vices capturing the central external contour supplemented
by 2 additional outlines collected 1 cm inside the superior
field border and 1 cm superior to the inframammary fold.11
The maximum thickness of lung included in the tangential
field was 2 cm; cardiac shielding used multileaf collimator
(MLC) or other technique. The dose distribution across the
target volume was modified to ensure homogeneity within
ICRU50/62 guidelines.12 Doses were prescribed to the
reference point at/near the center of the target volume.
Maximum and minimum doses were # 10% of doses on
the central plane after full dose compensation; where full
dose compensation was not possible, maximum doses in
the superior plane and plane through the inframammary
fold were recorded. Three main dose compensation
methods were used to improve dose homogeneity: (1)
physical breast compensators, (2) simple forward-planned
intensity-modulated radiation therapy (IMRT) MLC segment
fields/field-in-field technique, and (3) inverse-planned IMRT
MLC segment fields.13
Outcome Assessment
The primary end point was change in photographic breast
appearance. Secondary end points were physician as-
sessments of radiation-induced breast changes and ipsi-
lateral disease in the breast (relapse or new primary).
Photographs were taken at baseline and 2 and 5 years after
radiotherapy. Change in photographic breast appearance
compared with the postsurgical (preradiotherapy) baseline
was scored on a qualitative 3-point scale (no, mild, or
marked change), on the basis of changes in size, shrink-
age, and shape. Patients were ineligible for additional
photographic assessments after breast reconstructive
CONTEXT
Key Objective
To test the reduction in total dose of adjuvant whole-breast radiotherapy delivered by 5 once-weekly fractions needed to
match the late adverse effects of a standard 25-fraction schedule.
Knowledge Generated
A once-weekly 5-fraction schedule of 28 Gy is estimated to be radiobiologically equivalent to 50 Gy in 25 fractions in terms of
late adverse effects at 10 years of follow-up.
Relevance
a/b estimates for late adverse effects are consistent with historical estimates of fraction size sensitivity in patients prescribed
adjuvant whole-breast radiotherapy and can be used to inform additional trials of accelerated hypofractionation. Five-year
results from the UK FAST-Forward trial have confirmed the efficacy of a 5-fraction schedule delivered in 1 week in terms of
local tumor control. Our findings from the FAST trial may be relevant to the needs of patients who are unable to comply with
or gain access to standard 25-, 16-, 15- or 5-fraction schedules, and in whom once-weekly treatment is preferable.
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surgery and after additional ipsilateral disease. All photo-
graphs were scored by at least 2 observers blind to patient
identity and treatment allocation following procedures
established in the START Trials14 (Appendix Figure A1,
online only). Because a number of years had elapsed since
the scoring of the 2-year photographs for the previous
publication,9 these were rescored along with the 5-year
photographs to ensure consistency of assessment criteria
(Appendix Table A1, online only). Breast size and surgical
deficit were assessed from the baseline photographs using
a qualitative 3-point scale (small, medium, large), with surgical
deficit expressed relative to the contralateral breast size.
Late-onset NTE in the breast (shrinkage, induration, tel-
angiectasia, edema) were assessed by physicians at annual
follow-up and graded on a 4-point scale for the treated
breast relative to the contralateral breast (none, a little, quite
a bit, or very much; interpreted as none, mild, moderate or
marked). Incidence of symptomatic rib fracture, symptom-
atic lung fibrosis, and ischemic heart disease was recorded.
Physicians were not blinded to randomized treatment allo-
cation. No patient-reported outcomes were assessed within
the FAST trial. Clinical assessments of acute skin toxicity
have been previously reported.9
Ipsilateral disease was defined as a malignancy (invasive or
ductal carcinoma in situ) presenting anywhere in the ip-
silateral breast parenchyma and/or overlying skin, whether
considered ipsilateral breast relapse or new primary tumor.
Data on first regional relapse (axilla, supraclavicular fossa,
and internal mammary chain), distant metastases, new
primary cancer, and death were also collected.
Statistical Considerations
Using START pilot trial results,2 an average 2-year rate of
mild or marked change in photographic breast appearance
for the test groups of 20% was assumed, allowing a sample
size of 900 to detect a 10% difference in the prevalence of
change in photographic breast appearance between test
dose levels with 90% power, 2-sided a 5 0.05, allowing for
10% loss to follow-up/unevaluable. The trial was not sta-
tistically powered to test for differences in local tumor control.
Scores for change in photographic breast appearance at
2 and 5 years were modeled using generalized estimating
equations (GEE).15 Mild and marked categories were
combined, because marked change was rare. Pairwise
comparisons of mild/marked change between schedules
were described by odds ratios (ORs, with 95% CI) obtained
from the GEE models and the Wald test.
Cross-sectional analyses of physician-assessed breast NTE
at 5 and 10 years compared frequencies of moderate/
marked effects versus none/mild between pairs of
schedules using risk ratios and risk differences (with
95% CI), and Fisher’s exact test. Longitudinal analyses of
moderate/marked physician-assessed NTE (v none/mild)
used GEE models including all annual assessments,
comparing schedules across the whole follow-up period
using OR (with 95% CI) and the Wald test; a term repre-
senting years of follow-up was included, enabling time
trends to be modeled. Survival analysis methods analyzed
time to first moderate/marked physician-assessed NTE,
including Kaplan-Meier plots and estimates of cumulative
incidence rates. Hazard ratios (HRs, with 95% CI) were
obtained from Cox proportional hazards regression, and
schedules were compared using the log-rank test. In-
consistencies between the GEE and Cox models for some
end points appeared to be due to more patients in the 28.5-
Gy group having only 1 event, which has a greater influence
on the time-to-event analysis (where only 1 event is
needed) compared with the longitudinal models including
all events over follow-up.
Kaplan-Meier estimates (with 95% CI) of 5- and 10-year
cumulative incidence of ipsilateral disease in the breast
were calculated, and HR (with 95% CI) compared
schedules obtained from Cox proportional hazards re-
gression, with patients censored at date of distant metas-
tases, new primary cancer (contralateral breast or nonbreast),
death, or date of last follow-up.
Estimates of the a/b ratio for late NTE were obtained by
fitting GEE models to all follow-up assessments (photo-
graphic and physician), including terms for total dose and
total dose multiplied by fraction size. The a/b ratio was
calculated as estimate for total dose/estimate for total dose
3 fraction size, with 95% CI estimated from the model
(lower confidence limits were truncated at zero when the
calculated limit was negative). Isoeffect doses in 2.0-Gy
TABLE 1. Change in Photographic Breast Appearance at 2 and 5 Years
Fractionation
Schedule (Gy)
2 Years 5 Years
OR for Mild/Marked
Change (95%CI)
Comparison With
50 Gy, P a
Comparison Between
30 Gy and 28.5 Gy, P a
None
No. (%)
Mild
No. (%)
Marked
No. (%)
None
No. (%)
Mild
No. (%)
Marked
No. (%)
50 217 (90.4) 20 (8.3) 3 (1.3) 163 (82.3) 31 (15.7) 4 (2.0) 1
30 205 (82.7) 36 (14.5) 7 (2.8) 160 (75.5) 44 (20.8) 8 (3.8) 1.64 (1.08 to 2.49) .019
28.5 215 (88.1) 27 (11.1) 2 (0.8) 166 (81.0) 34 (16.6) 5 (2.4) 1.10 (0.70 to 1.71) .686 .052
NOTE. Data are presented as No. (%) unless otherwise noted.
Abbreviation: OR, odds ratio (estimated from generalized estimating equation model including 2 and 5-year data).
aP value from Wald test.
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equivalents were calculated for the experimental sched-
ules, and the 5-fraction schedule estimated to be iso-
effective with 50 Gy/25 fractions was derived.
All analyses were performed on an intention-to-treat basis,
from a database snapshot taken on July 17, 2018; Stata
version 15 (StataCorp, College Station, TX) was used.
RESULTS
A total of 915 women were recruited from October 2004 to
March 2007 from 18 UK radiotherapy centers. Baseline
clinical and demographic details were reported previously9
(Appendix Table A2, online only). Mean age at random
assignment was 62.9 years (range, 50-88 years), mean
pathologic tumor size was 1.3 cm (range, 0.1-3.0 cm),
34% of patients had a grade 1 tumor, and 88.4% of pa-
tients were scheduled to receive adjuvant endocrine
therapy. At the time of analysis, median follow-up was
9.9 years (interquartile range, 8.3-10.1 years). Of patients
alive and disease free, assessments of change in photo-
graphic breast appearance were available for 732/901
(81%) patients at 2 years and 615/862 (71%) at 5 years
(Appendix Figures A1 and A2).
At 5 years, 489/615 (79.5%) patients had no change in
photographic breast appearance, 109 (17.7%) had mild
change, and 17 (2.8%) had marked change. Rates of mild/
marked change in photographic breast appearance at 2 or
5 years were statistically significantly higher for 30 Gy
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FIG 1. Physician assessments of late normal tissue effects. (A) Breast shrinkage to 10 years; (B) time to first reported moderate/marked breast shrinkage;
(C) breast induration to 10 years; (D) time to first reported moderate/marked breast induration; (E) breast edema to 10 years; (F) time to first reported
moderate/marked breast edema; (G) telangiectasia to 10 years; and (H) time to first reported moderate/marked telangiectasia.
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compared with 50 Gy (OR, 1.64; 95% CI, 1.08 to 2.49; P5
.019) but not significantly different for 28.5 Gy and 50 Gy
(OR, 1.10; 95% CI, 0.70 to 1.71; P5 .686; Table 1). Rates
of mild/marked change in photographic breast appearance
were slightly higher for 30 Gy compared with 28.5 Gy
(P 5 .052).
Any moderate/marked physician-assessed NTE in the
breast (shrinkage, induration, telangiectasia, edema) was
reported for 92/774 (11.9%) at 5 years and 55/392
(14.0%) at 10 years (Table 2). The most prevalent indi-
vidual effect was breast shrinkage (Fig 1). Five-year
prevalence of any moderate/marked breast NTE was es-
timated to be 10% higher (95% CI, 5% to 16%) for 30 Gy
versus 50 Gy (P , .001), with no statistically significant
difference between 28.5 Gy and 50 Gy (2%; 95% CI,
22% to 17%; P 5 .349). At 5 years, risk ratios for
moderate/marked breast shrinkage versus 50 Gy were 2.03
(95% CI, 1.15 to 3.58; P 5 .017) for 30 Gy and 1.20
(95%CI, 0.63 to 2.27; P5 .604) for 28.5 Gy. There were no
statistically significant differences between schedules in
5-year prevalence of moderate/marked breast induration,
telangiectasia, and breast edema, nor in 10-year preva-
lence of any moderate/marked effects, with few marked
events (Table 2). At 10 years, the estimated absolute dif-
ferences in prevalence of anymoderate/marked breast NTE
compared with 50 Gy were 9% (95% CI, 1% to 18%:
P5 .032) for 30 Gy and 5% (95% CI,22% to113%; P5
.184) for 28.5 Gy.
Five- and 10-year cumulative incidence rates of moderate/
marked NTE in the breast were higher for 30 Gy compared
with 50 Gy, with statistically significant differences for any
NTE in the breast, breast shrinkage, breast induration, and
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breast edema (Fig 1; Appendix Table A3, online only).
Cumulative incidence rates of any moderate/marked NTE
in the breast and breast induration were significantly higher
for 28.5 Gy versus 50 Gy.
Modeling all annual physician assessments over follow-up,
rates of moderate/marked effects were statistically signifi-
cantly higher for 30 Gy compared with 50 Gy (OR for any
breast NTE, 2.12; 95% CI, 1.55 to 2.89; P, .001), but with
no significant difference between 28.5 Gy and 50 Gy (OR,
1.22; 95% CI, 0.87 to 1.72; P5 .248; Table 3). Statistically
significant differences between the test schedules were
found for breast shrinkage, telangiectasia, and breast
edema, with higher rates for 30 Gy compared with 28.5 Gy.
The prevalence of breast shrinkage and telangiectasia
increased over time, with a decline in breast edema (Fig 1).
Change in photographic breast appearance gave an un-
adjusted a/b estimate of 2.7 Gy (95% CI, 1.5 to 3.9 Gy);
adjusting for breast size and surgical deficit made little
difference (Table 4). Using an a/b of 2.7 Gy, the isoeffect
doses expressed in 2.0-Gy equivalents for 30 and 28.5 Gy
in 5 fractions were approximately 56 and 51Gy, respectively,
and the once-weekly 5-fraction schedule estimated to be
isoeffective with 50Gy/25 fractions was 28 Gy (95%CI, 26 to
30 Gy). Estimates of a/b for physician-assessed NTE were
consistent with the photographic end point (Table 4).
A total of 123 patients (13.4%) were referred to a specialist
for radiotherapy-related adverse effects, most frequently
lymphedema, with similar rates between the schedules
(Appendix Table A4, online only). Symptomatic rib fracture
was reported for 11 patients (1.2%), symptomatic lung
fibrosis for 8 (0.9%), and ischemic heart disease for 17
(1.9%), including 7 cases in patients treated for left-sided
breast cancer (Appendix Table A5, online only).
Ipsilateral breast events were reported for 11/915 (1.2%)
patients (50 Gy: 3; 30 Gy: 4; 28.5 Gy: 4), with estimated
cumulative incidence rates of 0.7% (95% CI, 0.3% to
1.6%) at 5 years and 1.3% (95% CI, 0.7% to 2.3%) at
10 years (Table 5). A total of 96 patients (10.5%) have died
(50 Gy: 30; 30 Gy: 33; 28.5 Gy: 33), including 25 (2.7%)
breast cancer deaths (50 Gy: 7; 30 Gy: 8; 28.5 Gy: 10).
Schedules appeared similar regarding breast cancer–
related events, new primary cancers, or deaths, although
numbers were small (Appendix Table A6, online only).
DISCUSSION
The FAST Trial tested once-weekly 5-fraction schedules of
whole-breast radiotherapy in terms of late NTE against
a standard regimen of 50 Gy in 25 fractions. Patient eligibility
focused on factors associated with a low absolute risk of local
tumor relapse, as experienced by an older patient age group
with early-stage pathologically node-negative disease.
Change in photographic breast appearance was the pri-
mary end point of late NTE as in the START trials, because
breast appearance after breast cancer treatment is of
importance to women, and photographs allow external
assessors to control for baseline surgical deficit and to score
postradiotherapy changes blind to treatment allocation.14
Marked change in photographic breast appearance in the
FAST trial was rare. The low rates of change recorded in the
FAST trial after 50 Gy incorporate the benefits of
3-dimensional dosimetry compared with 2-dimensional
dosimetry used in the START and Ontario trials, as well
as fewer women with large breast size included in FAST.
Physician assessments, although not blinded to allocated
treatment and hence potentially subject to bias, never-
theless provide a valuable assessment of late NTE from
a different perspective to the photographs, and both sets of
results contribute to the overall evidence from the trial.
Annual physician assessments identified few moderate or
marked effects over 10 years. The prevalence of breast
shrinkage and telangiectasia increased over follow-up in
FAST, as shown in other studies,4,16 whereas breast edema
declined, consistent with patient-reported outcomes of the
IMPORT LOW trial of partial breast radiotherapy.17 Incident
cases of ischemic heart disease were rare, but longer
follow-up is required to adequately monitor cardiac risk
after breast radiotherapy.
The a/b estimates from FAST are consistent with the
10-year analysis of the START-A trial, which generated
estimates around 3-4 Gy for late NTE in the breast.4 This
consistency supports the validity of the linear-quadratic
model for fraction sizes as high as 5.0-6.0 Gy. However,
fractionation sensitivity might be slightly higher (a/b value
slightly lower) than predicted by the model because of much
lower rates of moist desquamation and later consequential
late skin damage when larger fractions are used. Rates of
patchy/confluent moist desquamation in the FAST trial after
50.0 Gy, 30.0 Gy, and 28.5 Gywere 11.7%, 2.7%, and 2.8%,
respectively (including only 1 confluent case), confirming the
well-established insensitivity of early-reacting self-renewal
tissues to fraction size and the importance of total dose.9,18
The FAST trial was not powered for formal statistical
comparison of local tumor control; the 10-year cumulative
incidence estimate was 1.3%, in keeping with the low-risk
population for which the trial was designed. The extremely
low number of local tumor events reflects the patient de-
mographics, tumor characteristics, careful attention to
microscopic excision margins, the use of adjuvant endo-
crine therapy, and high-quality radiotherapy. Deaths from
other causes were the most frequent consequential event.
The FAST trial was conceived in the early 2000s, and since
then the UK5 and international standard7 has become
40 Gy in 15 fractions over 3 weeks or similarly hypo-
fractionated. On the basis of an a/b value of 2.7 Gy, the
15-fraction regimen is equivalent to 45.7 Gy in 2.0-Gy
equivalents. In response to 10-year results of the START and
Ontario trials, 15- or 16-fraction regimens are the preferred
dose-fractionation options for whole-breast radiotherapy
according to the American Society of Radiation Oncology.7
Journal of Clinical Oncology 9
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FAST informed the design of the UK phase III FAST-Forward
trial testing 2 dose levels of a 5-fraction schedule deliv-
ered in 1 week compared with 40 Gy in 15 fractions in
women prescribed adjuvant radiotherapy to whole breast or
postmastectomy chest wall after primary surgery for early
breast cancer. FAST-Forward demonstrated non-inferiority
of the 5-fraction schedules in terms of 5-year ipsilateral
tumor control, with similar rates of late NTE up to 5 years for
TABLE 3. Longitudinal Analysis of Moderate/Marked Physician-Assessed Late NTE Including All Follow-Up Assessments
NTE End Point
No. Moderate/Marked Events/Total
No. of Assessments
Over Follow-Up (%)
OR for RT Schedulea
(95% CI)
Comparison With
50 Gy, P b
Comparison Between 30 Gy
and 28.5 Gy, P b
OR for Years of Follow-Up
(95% CI), P b
Any NTE in the
breastc
, .001 1.04 (1.01 to 1.06), .002
50 Gy 202/2,255 (9.0) 1
30 Gy 392/2,313 (16.9) 2.12 (1.55 to 2.89) , .001
28.5 Gy 233/2,269 (10.3) 1.22 (0.87 to 1.72) .248
Breast shrinkage .002 1.09 (1.06 to 1.22), , .001
50 Gy 160/2,252 (7.1) 1
30 Gy 284/2,311 (12.3) 1.88 (1.32 to 2.67) , .001
28.5 Gy 175/2,266 (7.7) 1.11 (0.76 to 1.64) .589
Breast induration .169 1.00 (0.94 to 1.05), .924
50 Gy 33/2,254 (1.5) 1
30 Gy 78/2,310 (3.4) 2.39 (1.31 to 4.35) .004
28.5 Gy 54/2,265 (2.4) 1.67 (0.89 to 3.16) .112
Telangiectasia .009 1.15 (1.07 to 1.23), , .001
50 Gy 21/2,254 (0.9) 1
30 Gy 52/2,313 (2.3) 2.68 (1.33 to 6.34) .025
28.5 Gy 16/2,267 (0.7) 0.78 (0.26 to 2.35) .656
Breast edema .027 0.68 (0.62 to 0.76), , .001
50 Gy 16/2,253 (0.7) 1
30 Gy 67/2,311 (2.9) 3.70 (1.86 to 7.35) , .001
28.5 Gy 30/2,266 (1.3) 1.92 (0.91 to 4.07) .087
Abbreviations: GEE, generalized estimating equation; NTE, normal tissue effects; OR, odds ratio; RT, radiotherapy.
aOR estimated from GEE model including all follow-up data and represents relative odds of moderate/marked NTE (v none/mild) for each pairwise
comparison of fractionation schedules across all annual assessments over follow-up.
bP value from Wald test.
cAny NTE in breast includes shrinkage, induration, telangiectasia, edema.
TABLE 4. Estimates of a/b and EQD2 for Late NTE
NTE End Point
a/b Estimate
(95% CI) (Gy)
EQD2 for 30-Gy
Schedulea (Gy)
EQD2 for 28.5-Gy
Schedulea (Gy)
Photographic assessments
Mild/marked change in photographic breast appearance 2.7 (1.5 to 3.9) 55.7 51.0
Mild/marked change in photographic breast appearance,
adjusted for breast size and surgical deficit
2.5 (1.1 to 3.9) 56.4 51.7
Physician-assessed moderate/marked NTE
Any NTE in the breastb 2.5 (1.8 to 3.3) 56.4 51.7
Breast shrinkage 2.7 (1.9 to 3.5) 55.5 50.9
Breast induration 1.6 (0 to 4.4)c 63.7 58.1
Telangiectasia 3.1 (2.3 to 3.9) 53.5 49.1
Breast edema 1.9 60.3 55.2
Abbreviations: EQD2, isoeffect doses in 2.0-Gy equivalents; GEE, generalized estimating equation; NTE, normal tissue effects; OR, odds ratio.
aEQD2 calculated for the 30-Gy and 28.5-Gy schedules as: [Total Dose 3 (Dose per fraction 1 a/b)]/(2 1 a/b).
bAny NTE in the breast includes shrinkage, induration, telangiectasia, and edema.
cLower limit truncated at 0.
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the 26 Gy 5-fraction schedule compared with 40 Gy in 15
fractions, and is already considered standard in many UK
radiotherapy departments.19 A substudy within FAST-
Forward tests the same dose schedules as the main trial in
patients who also require radiotherapy to the axilla and/or
supraclavicular fossa.
In conclusion, the FAST trial identifies a 5-fraction schedule
estimated to be radiobiologically equivalent to the 25-fraction
standard in terms of late NTE. Identification of a 5-fraction
schedule equivalent with respect to tumor control is being
evaluated in the UK FAST-Forward trial. Although not
powered for tumor control, the FAST trial suggests that for
patients at low risk of relapse and for whom daily visits over
3 or 5 weeks are not possible because of frailty or comor-
bidities, 28 Gy in 5 fractions as a once-weekly schedule
might be an appropriate alternative to no treatment.
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TABLE 5. Survival Analysis of Ipsilateral Disease in the Breast Overall and by Fractionation Schedule
Fractionation Schedule
Ipsilateral
Breast Eventa/Total (%)
KM Estimate (95% CI) of Cumulative
Incidence (%)
Hazard Ratio
(95% CI)5 Years 10 Years
All patients 11/915 (1.2) 0.7 (0.3 to 1.6) 1.3 (0.7 to 2.3) —
50 Gy 3/302 (1.0) 0.7 (0.2 to 2.8) 0.7 (0.2 to 2.8) 1
30 Gy 4/308 (1.3) 1.0 (0.3 to 3.2) 1.4 (0.5 to 3.8) 1.36 (0.30 to 6.06)
28.5 Gy 4/305 (1.3) 0.4 (0.05 to 2.6) 1.7 (0.6 to 4.4) 1.35 (0.30 to 6.05)
Abbreviation: KM, Kaplan-Meier.
aIncludes 1 patient with angiosarcoma in the ipsilateral breast (30 Gy).
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APPENDIX Principal and Main Co-Investigators According to Center
(No. of patients recruited)
Cheltenham General Hospital, Cheltenham (n5 2), K. Benstead, J. R.
Owen; Gloucester Royal Hospital, Gloucester (n5 2), K. Benstead;
Worcestershire Royal Infirmary, Worcester (n 5 6), J. Bowen,
R. Counsell; Christie Hospital, Manchester (n 5 12), A. Stewart;
Clatterbridge Centre for Oncology, Bebington (n 5 6), I. Syndikus;
Warrington and Halton Hospitals, Warrington (n 5 18), I. Syndikus;
Ipswich Hospital, Ipswich (n 5 17), E. Sherwin; Leeds General
Hospital, Leeds (n 5 5), S. Kumar; Mid-Yorks Hospitals, Wakefield
(n5 4), S. Kumar, F. Roberts; Norfolk and Norwich University Hospital,
Norwich (n 5 27), A. Harnett, A. Bulman; James Paget, Norfolk and
Norwich (n 5 25), A. Harnett, A. Bulman; University Hospital of North
Staffordshire, Stoke-on-Trent (n 5 112), A. M. Brunt, A. Al Niaimi;
Royal Marsden Hospital, Sutton (n 5 75), J. R. Yarnold, D. Tait,
A. Rostom, M. Dryzmala; Royal Cornwall Hospital, Truro (n 5 109),
D. Wheatley, A. Thomson, T. Hurst; Royal Devon and Exeter Hospital,
Exeter (n5 61), A. Goodman, A. Hong, P. Bliss; North Devon Hospital,
(n 5 20), A. Hong; Burnley General Hospital, Burnley (n 5 14), M.
Hogg, W. Appel; Blackpool Royal Infirmary, Blackpool (n 5 6), Royal
Preston, A. Hindley, S. Susnerwala; Royal Shrewsbury Hospital,
Shrewsbury (n 5 36), R. K. Agrawal; Southend General Hospital,
Southend (n 5 66), A. Robinson; Basildon University Hospital,
Basildon (n 5 3), C. Trask; Torbay District General Hospital, Torbay
(n 5 58), P. Bliss, A. Goodman; Velindre Hospital, Cardiff (n 5 42),
J. Abraham, C. Gaffney, P. J. Barrett-Lee; Royal Gwent Hospital
(n 5 7), J. Abraham, C. Gaffney, P. J. Barrett-Lee; Royal Glamorgan
Hospital, (n5 4), J. Abraham; Royal Sussex County Hospital, Brighton
(n 5 34), D. Bloomfield, R. Simcock; Worthing Hospital, Worthing
(n 5 41), S. Mitra; Eastbourne Hospital, Eastbourne (n 5 2), A.
Robinson; Queens Hospital, Romford (n 5 9), M. Quigley, E. Sims;
Beatson Oncology Centre, Glasgow (n 5 85), A. Alhasso, D. Ritchie;
Victoria Infirmary, Glasgow (n 5 2), A. Alhasso; Crosshouse Hospital,
Kilmarnock (n 5 5), A. Alhasso, D. Ritchie.
Scoring Photographic Assessments of Change in Breast
Appearance: Additional Details of Methods and Update of
Published 2-Year Results
Methods
Photographs were scored by a team comprising 2-3 observers
(2 consultant clinical oncologists including J.R.Y., Chief Investigator of
FAST Trial, and a researchmanager in the chief investigator’s research
team). Each scoring session began with a review of photographs
previously scored, followed by scoring of the new photographs; ses-
sions generally lasted for 1 day. As previously described,12 observers
conferred and agreed on a score by consensus. The same processes
were followed for the 5-year photographs as for the original 2-year
photograph scoring, with one change of personnel (clinical oncologist).
The categories of mild andmarked changewere assessed qualitatively,
as it was not possible to quantitatively measure breast shrinkage from
the photographs. Examples of no change and marked change in
photographic breast appearance are shown in Appendix Figure A1.
Update of 2-Year Results
Three additional 2-year photographs were scored since the 2011
publication,9 taking the total at year 2 to 732.
When the year 5 photographs were scored, it was noted that the overall
prevalence of mild and marked changes was unexpectedly lower than
reported at 2 years in the 2011 publication. Marked changes in
particular would not be expected to reverse, except for some patients
with marked breast edema. Because there was no objective measure
used, such as a quantitative measurement of breast shrinkage, for
example, it is considered more likely that perceptions of radiotherapy-
related changes changed over the long time period since the 2-year
photographs were originally scored, causing discrepancies between
the published 2-year results and the 5-year results reported here.
Hence it was decided to rescore all 2-year photographs originally
scored as mild or marked change, together with a random sample of
those originally scored as no change.
Overall, 472 paired scores (original and rescore) were available for year
2. The number of scores expected to agree by chance were calculated,
along with the weighted k statistic to test agreement between the pairs.
There were fewer mild and marked changes in the rescores at year 2
(Appendix Table A1). The number of pairs of scores expected to agree
by chance were 227 (no change), 26 (mild), 0.8 (marked) (ie, ob-
served agreement for mild andmarked changes was higher than would
be expected by chance; weighted k, 0.46; “moderate” agreement;
SE 0.03).
In summary, although the observed agreement between the original
scores and the rescores for mild and marked changes was higher than
would be expected by chance, it was decided to use the rescores for all
analyses presented in this article, as the level of agreement overall was
only moderate. The number of patients with mild/marked change in
photographic breast appearance at 2 years reported here is less than in
the 2011 article, but conclusions regarding differences between the
fractionation schedules are as before.9
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After surgery, before 
radiotherapy:
No change Marked change
Years later:
FIG A1. Examples of no change and marked change in photographic breast appearance.
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No. randomly
assigned
Allocated
fractionation
schedule
Received
allocated
treatment as per
protocol*
Baseline
photographic
assessment
available
Year-5
photographic
assessment
available 
Follow-up data
available
(n = 915)
(n = 295)
Did not receive allocated
    treatment                  (n = 7)
  Needed a “cup” for RT (1)
  Refused allocated trt (1)
  Withdrew after random 
    assignment               (n = 3)
  Ineligible due to second
    primary                     (n = 1)
  Replanned on day 1 of RT
    due to poor set-up and no
    multiple outlines 
    taken                         (n = 1)
50 Gy 25 fr 5 weeks
(n = 302)
(n = 281)
Patients with no baseline
    photo                       (n = 21)
  Ineligible/deviated      (n = 1)
  Withdrew consent after
    random assignment  (n = 4)
  Administrative issue   (n = 6)
  Reason not known    (n = 10) 
(n = 198)
Patients with no 5-year
   assessment available (n = 104)
  No baseline photo         (n = 21)
  Withdrawn                        (n = 4)
  Died                                   (n = 9)
  Relapse/second cancer  (n = 10)
  Reconstruction                 (n = 2)
  FU at different hospital   (n = 2)
  Moved/lost to follow-up  (n = 1)
  Photograph taken but
    unevaluable                   (n = 1)
  Reason not known         (n = 54)
(n = 301)
(n = 303)
Did not receive allocated
    treatment                      (n = 5)
  Needed a “cup” for RT  (n = 2) 
  Had manual outline for
    planning as CT not
    possible                        (n = 1)
  Ineligible as needed RT to
    both breasts                 (n = 1)
  Standard trt given due to
    planning problems      (n = 1)  
30 Gy 5 fr 5 weeks
(n = 308)
(n = 290)
Patients with no baseline
    photo                        (n = 18)
  Ineligible/deviated       (n = 1)
  Administrative issue   (n = 6)
  Reason not known     (n = 11) 
(n = 212)
Patients with no 5-year
   assessment available   (n = 96)
  No baseline photo         (n = 18)
  Withdrawn                         (n = 2)
  Died                                    (n = 7)
  Relapse/second cancer (n = 14)
  FU at different hospital   (n = 1)
  Moved/lost to follow-up (n = 2)
  Reason not known         (n = 52)  
(n = 305)
Patients with no follow-up
    data available             (n = 3)
  Withdrew after random 
     assignment                (n = 1)
  Moved                           (n = 2) 
Patient with no follow-up
    data available             (n = 1)
  Withdrawn after random 
     assignment                (n = 1)
28.5 Gy 5 fr 5 weeks
(n = 305)
(n = 301)
Did not receive allocated
    treatment                     (n = 4)
  Ineligible due to second
    primary                       (n = 1)
  Limited arm movement so
    standard superior border
    not used                      (n = 1)
  Prescribed tumor bed boost
    after random 
assignment   (n = 1)
  Standard treatment given due
    to dose inhomogeneity for 
    allocated treatment    (n = 1) 
(n = 282)
Patients with no baseline
    photo                       (n = 23) 
  Ineligible/deviated      (n = 3)
  Administrative issue  (n = 2)
  Reason not known    (n = 17)
(n = 205)
Patients with no 5-year
   assessment available  (n = 100)
  No baseline photo          (n = 23)
  Withdrawn                        (n = 4)
  Died                                 (n = 17)
  Relapse/second cancer    (n = 8)
  FU at different hospital    (n = 2)
  Moved/lost to follow-up   (n = 3)
  Reason not known           (n = 43)  
(n = 302)
Patients with no follow-up
   data available             (n = 3)
  Withdrew after random 
     assignment               (n = 1)
  Moved                          (n = 2)  
FIG A2. FAST Trial profile. FU, follow-up; fr, fraction; RT, radiotherapy; trt, treatment. (*) Only major treatment deviations are listed. Minor
deviations due to public holidays, machine service days, and machine breakdowns not included.
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TABLE A1. Comparison of Original Scores and Rescores for Change in Photographic Breast Appearance at 2 Years
Original Score
Rescore
TotalNo Change Mild Change Marked Change
No change 277 (98.6) 4 (1.4) 0 (0) 281
Mild change 103 (66.0) 52 (33.3) 1 (0.6) 156
Marked change 2 (5.7) 23 (65.7) 10 (28.8) 35
Total 382 79 11 472
NOTE. Data are presented as No. (%) or No.
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TABLE A2. Baseline Characteristics by Fractionation Schedule
Characteristic
50 Gy
(n 5 302)
30 Gy
(n 5 308)
28.5 Gy
(n 5 305)
Age, years
50-59 112 (37.1) 112 (36.4) 110 (36.1)
60-69 143 (47.4) 145 (47.1) 153 (50.2)
70-79 44 (14.6) 42 (13.6) 39 (12.8)
$ 80 3 (1.0) 9 (2.9) 3 (1.0)
Mean (SD) 63.1 (7.2) 62.9 (7.5) 62.7 (6.8)
Range 50.0-88.4 50.1-84.9 50.0-82.3
Time from surgery to random assignment, weeks
Median (interquartile range) 6.0 (4.4-7.6) 5.7 (4.1-7.2) 6.0 (4.1-7.6)
Range 1.3-22.1 0.4-21.1 0.7-19.0
Histologic type
Ductal 230 (76.2) 241 (78.2) 229 (75.1)
Lobular 36 (11.9) 29 (9.4) 30 (9.8)
Special type 22 (7.3) 31 (10.1) 29 (9.5)
Mixed 10 (3.3) 7 (2.3) 15 (4.9)
DCIS 3 (1.0) 0 (0.0) 1 (0.3)
Other 1 (0.3) 0 (0.0) 1 (0.3)
Axillary surgery
None 1 (0.3) 0 3 (1.0)
SNB 49 (16.2) 52 (16.9) 57 (18.7)
Sampling 140 (46.0) 133 (43.2) 134 (43.9)
Clearance 85 (28.1) 85 (27.6) 80 (26.2)
SNB and sampling 24 (7.9) 35 (11.4) 28 (9.2)
SNB and clearance 1 (0.3) 2 (0.6) 2 (0.6)
Other 2 (0.7) 1 (0.3) 1 (0.3)
Pathologic tumor size, cm
, 1 90 (29.8) 84 (27.3) 87 (28.5)
1-2 166 (55.0) 165 (53.6) 160 (52.5)
$ 2 46 (15.2) 59 (19.2) 58 (19.0)
Mean (SD) 1.3 (0.6) 1.3 (0.6) 1.3 (0.7)
Range 0.05-3.0 0.13-3.0 0.1-3.0
Tumor grade
1 94 (31.1) 113 (36.7) 102 (33.4)
2 176 (58.3) 159 (51.6) 168 (55.1)
3 29 (12.9) 35 (11.4) 34 (11.1)
Not known 3 (1.0) 1 (0.3) 1 (0.3)
Adjuvant therapy
None 39 (12.9) 37 (12.0) 30 (9.8)
Tamoxifen 227 (75.2) 243 (78.9) 224 (73.4)
AI 31 (10.3) 26 (8.4) 45 (14.8)
Tamoxifen → AI 4 (1.3) 2 (0.6) 4 (1.3)
Unknown type 1 (0.3) 0 (0.0) 2 (0.7)
Breast size
Small 154 (51.0) 172 (55.8) 163 (53.4)
(continued on following page)
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TABLE A2. Baseline Characteristics by Fractionation Schedule (continued)
Characteristic
50 Gy
(n 5 302)
30 Gy
(n 5 308)
28.5 Gy
(n 5 305)
Medium 89 (29.5) 87 (28.2) 93 (30.5)
Large 38 (12.6) 31 (10.1) 24 (7.9)
Unknowna 21 (7.0) 18 (5.8) 23 (7.5)
Surgical deficit
Small 156 (51.7) 148 (48.1) 154 (50.5)
Medium 68 (22.5) 83 (26.9) 77 (25.2)
Large 57 (18.9) 59 (19.2) 51 (16.7)
Unknowna 21 (7.0) 18 (5.8) 23 (7.5)
NOTE. Data are presented as No. (%) unless otherwise noted.
Abbreviations: AI, aromatase inhibitor; DCIS, ductal carcinoma in situ; SD, standard deviation; SNB, sentinel node biopsy.
aBreast size and surgical deficit scored from baseline photographs. Unknown indicates no baseline photograph available.
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TABLE A3. Survival Analyses of Moderate/Marked Physician-Assessed Late NTE by Fractionation Schedule
NTE End Point
Moderate/Marked
Events/Totala (%)
KM Estimate (95% CI) of Cumulative
Incidence (%) of Moderate/Marked Events
Hazard Ratio (95% CI)
Comparison With
50 Gy, P d
Comparison Between
30 Gy and 28.5 Gy, P d5 Yearsb 10 Yearsc
Any NTE in the breaste
50 Gy 88/301 (29.2) 20.1 (15.9 to 25.1) 33.6 (27.5 to 40.8) 1
30 Gy 134/304 (44.1) 37.2 (31.9 to 43.0) 50.4 (44.0 to 57.1) 1.79 (1.37 to 2.34) , .001
28.5 Gy 116/298 (38.9) 27.9 (23.1 to 33.6) 47.6 (40.6 to 55.2) 1.45 (1.10 to 1.91) .008 .099
Breast shrink
50 Gy 69/301 (22.9) 13.7 (10.2 to 18.2) 28.5 (22.2 to 36.1) 1
30 Gy 104/304 (34.2) 27.4 (22.7 to 33.0) 40.5 (34.3 to 47.4) 1.71 (1.26 to 2.32) , .001
28.5 Gy 79/298 (26.5) 17.9 (13.9 to 22.9) 33.4 (27.0 to 40.9) 1.22 (0.88 to 1.68) .232 .025
Breast induration
50 Gy 19/301 (6.3) 4.8 (2.9 to 8.0) 7.4 (4.7 to 11.4) 1
30 Gy 40/304 (13.2) 9.2 (6.4 to 13.1) 15.2 (11.3 to 20.3) 2.22 (1.29 to 3.84) .003
28.5 Gy 38/298 (12.7) 9.2 (6.3 to 13.2) 18.6 (12.7 to 26.7) 2.14 (1.23 to 3.71) .006 .864
Telangiectasia
50 Gy 10/301 (3.3) 2.1 (1.0 to 4.5) 3.8 (2.0 to 7.0) 1
30 Gy 15/304 (4.9) 4.1 (2.4 to 7.2) 5.8 (3.5 to 9.7) 1.55 (0.70 to 3.45) .288
28.5 Gy 13/298 (4.4) 2.2 (1.0 to 4.8) 5.5 (3.2 to 9.5) 1.35 (0.59 to 3.09) .460 .721
Breast edema
50 Gy 14/301 (4.6) 4.4 (2.6 to 7.4) 4.8 (2.9 to 8.0) 1
30 Gy 40/304 (13.2) 12.8 (9.5 to 17.2) 13.7 (10.2 to 18.2) 2.98 (1.62 to 5.48) , .001
28.5 Gy 24/298 (8.0) 6.8 (4.4 to 10.3) 8.6 (5.8 to 12.6) 1.78 (0.92 to 3.43) .084 .043
Other
50 Gy 14/301 (4.6) 3.5 (1.9 to 6.4) 6.5 (3.4 to 12.5) 1
30 Gy 37/304 (12.2) 8.1 (5.5 to 11.8) 14.1 (10.4 to 19.1) 2.80 (1.51 to 5.18) , .001
28.5 Gy 25/298 (8.4) 6.4 (4.0 to 9.9) 9.9 (6.7 to 14.4) 1.88 (0.98 to 3.62) .054 .123
Abbreviations: KM, Kaplan-Meier; NTE, normal tissue effects.
aFollow-up NTE data available for 903/915 patients.
bRate estimated at 5 years and 3 months.
cRate estimated at 10 years and 3 months.
dP value for pairwise log-rank test.
eAny NTE in the breast includes shrinkage, induration, telangiectasia, and edema
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TABLE A4. Specialist Referral During Follow-Up, by Fractionation Schedule
Specialist Referral Typea
50 Gy
(n 5 302)
30 Gy
(n 5 308)
28.5 Gy
(n 5 305)
Total
(N 5 915)
Lymphedema 15 (5.0) 31 (10.1) 7 (2.3) 53 (5.8)
Breast surgery/breast surgeon 2 (0.7) 11 (3.6) 4 (1.3) 17 (1.9)
Cardiology 6 (2.0) 2 (0.6) 2 (0.6) 10 (1.1)
Pulmonary/respiratory 3 (1.0) 4 (1.2) 1 (0.3) 8 (0.9)
Biopsy 0 1 (0.3) 2 (0.6) 3 (0.3)
Dermatology 1 (0.3) 2 (0.6) 0 3 (0.3)
GP 1 (0.3) 0 1 (0.3) 2 (0.2)
Pain 1 (0.3) 0 2 (0.6) 3 (0.3)
Other 4 (1.4) 9 (2.9) 11 (3.6) 24 (2.6)
NOTE. Data are presented as No. (%).
Abbreviation: GP, general practitioner.
aWhere patients had . 1 type of referral, each is listed separately.
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TABLE A5. Incidence of Other Late Adverse Effects, by Fractionation Schedule
Adverse Effect
50 Gy
(n 5 302)
30 Gy
(n 5 308)
28.5 Gy
(n 5 305)
Total
(N 5 915)
Symptomatic rib fracture 4 (1.3) 5 (1.6) 2 (0.7) 11 (1.2)
Symptomatic lung fibrosis 3 (1.0) 3 (1.0) 2 (0.7) 8 (0.9)
Ischemic heart disease
Total 8 (2.6) 6 (1.9) 3 (1.0) 17 (1.9)
Left sided 4 (1.3) 2 (0.6) 1 (0.3) 7 (0.8)
NOTE. Data are presented as No. (%).
TABLE A6. Relapses, Second Primary Cancers, and Deaths, by Fractionation Schedule
Event
Fractionation Schedule
Total
(N 5 915)
50 Gy
(n 5 302)
30 Gy
(n 5 308)
28.5 Gy
(n 5 305)
Relapse
Local (breast skin or parenchyma) 3 (1.0) 3 (1.0) 4 (1.3) 10 (1.1)
Regional (axilla or supraclavicular fossa) 2 (0.7) 0 3 (1.0) 5 (0.5)
Distant 17 (5.6) 15 (4.9) 15 (4.9) 47 (5.1)
Second primary cancer 23 (7.6) 21a (6.8) 25 (8.2) 69a (7.5)
Deaths 30 (9.9) 33 (10.7) 33 (10.8) 96 (10.5)
Breast cancer 7 (2.3) 8 (2.6) 10 (3.3) 25 (2.7)
Other cause 23 (7.6) 25 (8.1) 23 (7.5) 71 (7.8)
Second cancer 13 5 9 27
Cardiovascular 2 6 6 14
Pulmonary 2 8 2 12
Other 6 6 6 18
NOTE. Data are presented as No. (%) or No.
aIncludes 1 patient with angiosarcoma in the ipsilateral breast.
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